Literature DB >> 19812446

Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.

Patrice Cacoub1, Fabrice Carrat, Pierre Bédossa, Jérôme Lambert, Guillaume Pénaranda, Stanislas Pol, Philippe Halfon.   

Abstract

BACKGROUND: The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients.
METHODS: A total of 238 HIV-HCV-coinfected patients (74% male, mean +/-sd age 40 +/-5 years, mean alcohol intake <50 g/day and 38% HCV genotype 2 or 3), treated by standard or pegylated interferon-alpha2b plus ribavirin during 48 weeks were studied. Liver biopsies were assessed before treatment. Patients were considered to have IR when the homeostasis model assessment of IR (HOMA-IR) was >2.5. Multiple logistic regression with stepwise selection was used to estimate independent factors associated with sustained virological response (SVR).
RESULTS: IR was present in 32% and significant liver fibrosis (Metavir>or=F2) in 74% of patients. Patients with SVR (96/238 [40%]) were more likely to be infected with HCV genotype 2 or 3 (54% versus 27%; P<0.0001), and had more severe liver fibrosis (>or=F3; 45% versus 30%; P=0.03). By multivariate analysis, a HOMA-IR>2.5 had a negative effect on the SVR (odds ratio 0.49 [95% confidence interval 0.26-0.92]; P=0.05).
CONCLUSIONS: A high HOMA-IR level is frequently found in HIV-HCV-coinfected patients and is associated with a reduced SVR rate. Improving insulin sensitivity might be a useful adjunct to HCV therapy in HIV-HCV-coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812446     DOI: 10.3851/IMP1298

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  7 in total

1.  Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.

Authors:  Marie-Louise C Vachon; Stephanie H Factor; Andrea D Branch; Maria-Isabel Fiel; Maribel Rodriguez-Torres; Norbert Bräu; Richard K Sterling; Jihad Slim; Andrew H Talal; Douglas T Dieterich; Mark S Sulkowski
Journal:  J Hepatol       Date:  2010-08-21       Impact factor: 25.083

Review 2.  Extrahepatic manifestations of chronic hepatitis C virus infection.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; Anne C Desbois; David Saadoun
Journal:  Ther Adv Infect Dis       Date:  2016-02

3.  Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

Authors:  Kristen M Marks; Douglas Kitch; Raymond T Chung; Colleen Hadigan; Janet Andersen; Phyllis Tien; Annie Luetkemeyer; Beverly Alston-Smith; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

4.  Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.

Authors:  Adeel A Butt; Triin Umbleja; Janet W Andersen; Kenneth E Sherman; Raymond T Chung
Journal:  Clin Infect Dis       Date:  2012-05-04       Impact factor: 9.079

Review 5.  The treatment of chronic hepatitis C virus infection in HIV co-infection.

Authors:  Martin Vogel; Jürgen K Rockstroh
Journal:  Eur J Med Res       Date:  2009       Impact factor: 2.175

Review 6.  New insights into HCV-related rheumatologic disorders: A review.

Authors:  Patrice Cacoub; Cloé Comarmond
Journal:  J Adv Res       Date:  2016-07-25       Impact factor: 10.479

7.  Insulin resistance, steatosis and hepatitis C virus.

Authors:  Alessandra Mangia; Maria Ripoli
Journal:  Hepatol Int       Date:  2013-08-27       Impact factor: 6.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.